Pathophysiology of mood disorders and mechanisms of action of antidepressants and mood stabilizers

Endocannabinoid Regulation of Monoamines in Psychiatric and Neurological Disorders

Volumn , Issue , 2013, Pages 103-134

  Fišar, Zdeněk ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Antidepressant; Depression; Endocannabinoid; Mood disorder; Mood stabilizer

Indexed keywords

EID: 84929590318     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-7940-6_6     Document Type: Chapter

References (192)

1. Aanhet Rot M, Mathew SJ, Charney DS (2009) Neurobiological mechanisms in major depressive disorder. Can Med Assoc J 180(3):305-313
2. Abdel-Razaq W, Kendall DA, Bates TE (2011) The effects of antidepressants on mitochondrial function in a model cell system and isolated mitochondria. Neurochem Res 36(2):327-338
3. Alexopoulos GS, Meyers BS, Young RC, Campbell S, Silbersweig D, Charlson M (1997) 'Vascular depression' hypothesis. Arch Gen Psychiatry 54:915-922
4. Almeida OP, McCaul K, Hankey GJ, Norman P, Jamrozik K, Flicker L (2008) Homocysteine and depression in later life. Arch Gen Psychiatry 65:1286-1294
5. Aso E, Ozaita A, Valdizán EM, Ledent C, Pazos A, Maldonado R, Valverde O (2008) BDNF impairment in the hippocampus is related to enhanced despair behavior in CB1 knockout mice. J Neurochem 105(2):565-572
6. Bachmann RF, Wang Y, Yuan P, Zhou R, Li X, Alesci S, Du J, Manji HK (2009) Common effects of lithium and valproate on mitochondrial functions: protection against methamphetamineinduced mitochondrial damage. Int J Neuropsychopharmacol 12(6):805-822
7. Bambico FR, Katz N, Debonnel G, Gobbi G (2007) Cannabinoids elicit antidepressant-like behavior and activate serotonergic neurons through the medial prefrontal cortex. J Neurosci 27(43):11700-11711
8. Bambico FR, Duranti A, Tontini A, Tarzia G, Gobbi G (2009) Endocannabinoids in the treatment of mood disorders: evidence from animal models. Curr Pharm Des 15(14):1623-1646
9. Bao AM, Meynen G, Swaab DF (2008) The stress system in depression and neurodegeneration: focus on the human hypothalamus. Brain Res Rev 57:531-553
10. Barann M, Molderings G, Brüss M, Bönisch H, Urban BW, Göthert M (2002) Direct inhibition by cannabinoids of human 5-HT3A receptors: probable involvement of an allosteric modulatory site. Br J Pharmacol 137(5):589-596
11. Belmaker RH, Agam G (2008) Major depressive disorder. N Engl J Med 358(1):55-68
12. Berk M, Kapczinski F, Andreazza AC, Dean OM, Giorlando F, Maes M, Yücel M, Gama CS, Dodd S, Dean B, Magalhães PV, Amminger P, McGorry P, Malhi GS (2011) Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev 35(3):804-817
13. Bortolato M, Mangieri RA, Fu J, Kim JH, Arguello O, Duranti A, Tontini A, Mor M, Tarzia G, Piomelli D (2007) Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress. Biol Psychiatry 62(10):1103-1110
14. Bottiglieri T (2005) Homocysteine and folate metabolism in depression. Prog Neuropsychopharmacol Biol Psychiatry 29:1103-1112
15. Bottiglieri T, Laundy M, Crellin R, Toone BK, Carney MW, Reynolds EH (2000) Homocysteine, folate, methylation, and monoamine metabolism in depression. J Neurol Neurosurg Psychiatry 69:228-232
16. Bremmer MA, Deeg DJ, Beekman AT, Penninx BW, Lips P, Hoogendijk WJ (2007) Major depression in late life is associated with both hypo-and hypercortisolemia. Biol Psychiatry 62:479-486
17. Buggy Y, Cornelius V, Wilton L, Shakir SA (2011) Risk of depressive episodes with rimonabant: a before and after modified prescription event monitoring study conducted in England. Drug Saf 34(6):501-509
18. Bunney JN, Potkin SG (2008) Circadian abnormalities, molecular clock genes and chronobiological treatments in depression. Br Med Bull 86:23-32
19. Butovsky E, Juknat A, Goncharov I, Elbaz J, Eilam R, Zangen A, Vogel Z (2005) In vivo upregulation of brain-derived neurotrophic factor in specific brain areas by chronic exposure to ?9-tetrahydrocannabinol. J Neurochem 93:802-811
20. Cannon DM, Carson RE, Nugent AC, Eckelman WC, Kiesewetter DO, Williams J, Rollis D, Drevets M, Gandhi S, Solorio G, Drevets WC (2006) Reduced muscarinic type 2 receptor binding in subjects with bipolar disorder. Arch Gen Psychiatry 63(7):741-747
21. Cannon DM, Klaver JK, Gandhi SK, Solorio G, Peck SA, Erickson K, Akula N, Savitz J, Eckelman WC, Furey ML, Sahakian BJ, McMahon FJ, Drevets WC (2011) Genetic variation in cholinergic muscarinic-2 receptor gene modulates muscarinic2-receptor binding in vivo and accounts for reduced binding in bipolar disorder. Mol Psychiatry 16(4):407-418
22. Carlezon WA Jr, Duman RS, Nestler EJ (2005) The many faces of CREB. Trends Neurosci 28(8):436-445
23. Carney MW, Chary TK, Laundy M, Bottiglieri T, Chanarin I, Reynolds EH, Toone B (1990) Red cell folate concentrations in psychiatric patients. J Affect Disord 19:207-213
24. Carvalho AF, Van Bockstaele EJ (2012) Cannabinoid modulation of noradrenergic circuits: implications for psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 38(1):59-67
25. Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, McClay J, Mill J, Martin J, Braithwaite A, Poulton R (2003) Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 301(5631):386-389
26. Castrén E, Rantamäki T (2010) Role of brain-derived neurotrophic factor in the aetiology of depression: implications for pharmacological treatment. CNS Drugs 24(1):1-7
27. Catena-Dell'Osso M, Bellantuono C, Consoli G, Baroni S, Rotella F, Marazziti D (2011) Inflammatory and neurodegenerative pathways in depression: a new avenue for antidepressant development? Curr Med Chem 18(2):245-255
28. Chevaleyre V, Takahashi KA, Castillo PE (2006) Endocannabinoid-mediated synaptic plasticity in the CNS. Annu Rev Neurosci 29:37-76
29. Citri A, Malenka RC (2008) Synaptic plasticity: multiple forms, functions, and mechanisms. Neuropsychopharmacology 33(1):18-41
30. Clay HB, Sillivan S, Konradi C (2011) Mitochondrial dysfunction and pathology in bipolar disorder and schizophrenia. Int J Dev Neurosci 29(3):311-324
31. Coppen A (1967) The biochemistry of affective disorders. Br J Psychiatry 113(504):1237-1264
32. Coppen A, Bolander-Gouaille C (2005) Treatment of depression: time to consider folic acid and vitamin B12. J Psychopharmacol 19:59-65
33. Cowen PJ (2008) Serotonin and depression: pathophysiological mechanism or marketing myth? Trends Pharmacol Sci 29(9):433-436
34. Crisafulli C, Fabbri C, Porcelli S, Drago A, Spina E, De Ronchi D, Serretti A (2011) Pharmacogenetics of antidepressants. Front Pharmacol 2(6):1-21
35. Graaf R de, Radovanovic M, Laar M van, Fairman B, Degenhardt L, Aguilar-Gaxiola S, Bruffaerts R, Girolamo G de, Fayyad J, Gureje O, Haro JM, Huang Y, Kostychenko S, Lépine JP, Matschinger H, Mora ME, Neumark Y, Ormel J, Posada-Villa J, Stein DJ, Tachimori H, Wells JE, Anthony JC (2010) Early cannabis use and estimated risk of later onset of depression spells: epidemiologic evidence from the population-based World Health Organization World Mental Health Survey Initiative. Am J Epidemiol 172(2):149-159
36. Degenhardt L, Coffey C, Romaniuk H, Swift W, Carlin JB, Hall WD, Patton GC (2013) The persistence of the association between adolescent cannabis use and common mental disorders into young adulthood. Addiction. 108(1):124-133
37. Delaveau P, Jabourian M, Lemogne C, Guionnet S, Bergouignan L, Fossati P (2011) Brain effects of antidepressants in major depression: a meta-analysis of emotional processing studies. J Affect Disord 130(1-2):66-74
38. Delgado PL, Miller HL, Salomon RM, Licinio J, Krystal JH, Moreno FA, Heninger GR, Charney DS (1999) Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: implications for the role of serotonin in the mechanism of antidepressant action. Biol Psychiatry 46(2):212-220
39. Denson TF, Earleywine M (2006) Decreased depression in marijuana users. Addict Behav 31(4):738-742
40. Derkinderen P, Valjent E, Toutant M, Corvol JC, Enslen H, Ledent C, Trzaskos J, Caboche J, Girault JA (2003) Regulation of extracellular signal-regulated kinase by cannabinoids in hippocampus. J Neurosci 23(6):2371-2382
41. Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, Kronstein P, Khalife S, Kammerer WA, Quezado Z, Luckenbaugh DA, Salvadore G, Machado-Vieira R, Manji HK, Zarate CA Jr (2010) A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 67(8):793-802
42. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, Lanctôt KL (2010) A metaanalysis of cytokines in major depression. Biol Psychiatry 67(5):446-457
43. Dragicevic N, Bradshaw PC, Mamcarz M, Lin X, Wang L, Cao C, Arendash GW (2011) Longterm electromagnetic field treatment enhances brain mitochondrial function of both Alzheimer's transgenic mice and normal mice: a mechanism for electromagnetic field-induced cognitive benefit? Neuroscience 185:135-149
44. Drzyzga ŠR, Marcinowska A, Obuchowicz E (2009) Antiapoptotic and neurotrophic effects of antidepressants: a review of clinical and experimental studies. Brain Res Bull 79(5):248-257
45. Duman RS (2002) Synaptic plasticity and mood disorders. Mol Psychiatry 7(Suppl 1):S29-S34
46. Duman RS (2009) Neuronal damage and protection in the pathophysiology and treatment of psychiatric illness: stress and depression. Dialogues Clin Neurosci 11(3):239-255
47. Duman RS, Monteggia LM (2006) A neurotrophic model for stress-related mood disorders. Biol Psychiatry 59(12):1116-1127
48. Duman RS, Heninger GR, Nestler EJ (1997) A molecular and cellular theory of depression. Arch Gen Psychiatry 54:597-606
49. Duman RS, Li N, Liu RJ, Duric V, Aghajanian G (2012) Signaling pathways underlying the rapid antidepressant actions of ketamine. Neuropharmacology 62(1):35-41
50. Einat H, Manji HK (2006) Cellular plasticity cascades: genes-to-behavior pathways in animal models of bipolar disorder. Biol Psychiatry 59(12):1160-1171
51. ElBatsh MM, Moklas MA, Marsden CA, Kendall DA (2012) Antidepressant-like effects of ?9-tetrahydrocannabinol and rimonabant in the olfactory bulbectomised rat model of depression. Pharmacol Biochem Behav 102(2):357-365
52. Elder BL, Mosack V (2011) Genetics of depression: an overview of the current science. Issues Ment Health Nurs 32(4):192-202
53. Engelmann M, Landgraf R, Wotjak CT (2004) The hypothalamic-neurohypophysial system regulates the hypothalamic-pituitary-adrenal axis under stress: an old concept revisited. Front Neuroendocrinol 25(3-4):132-149
54. Esteban S, Garcaà-Sevilla JA (2012) Effects induced by cannabinoids on monoaminergic systems in the brain and their implications for psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 38(1):78-87
55. Fattal O, Budur K, Vaughan AJ, Franco K (2006) Review of the literature on major mental disorders in adult patients with mitochondrial diseases. Psychosomatics 47(1):1-7
56. Fava M, Kendler KS (2000) Major depressive disorder. Neuron 28(2):335-341
57. Fišar Z (2009) Phytocannabinoids and endocannabinoids. Curr. Drug Abuse Rev 2(1):51-75
58. Fišar Z (2010) Inhibition of monoamine oxidase activity by cannabinoids. Naunyn Schmiedebergs Arch Pharmacol 381(6):563-572
59. Fišar Z (2012) Cannabinoids and monoamine neurotransmission with focus on monoamine oxidase. Prog Neuropsychopharmacol Biol Psychiatry 38(1):68-77
60. Fišar Z, Hroudová J (2010a) Common aspects of neuroplasticity, stress, mood disorders and mitochondrial functions. Act Nerv Super Rediviva 52(1):3-20
61. Fišar Z, Hroudová J (2010b) Intracellular signalling pathways and mood disorders. Folia Biol 56(4):135-148
62. Fišar Z, Raboch J (2008) Depression, antidepressants, and peripheral blood components. Neuro Endocrinol Lett 29(1):17-28
63. Fišar Z, Hroudová J, Raboch J (2012) Neurotransmission in mood disorders. In: Mario Francisco Juruena (ed) Clinical, research and treatment approaches to affective disorders. InTech, Rijeka, pp 191-234. Available from: http://www.intechopen.com/articles/show/title/neurotransmission-inmood-disorders
64. Fitzgerald ML, Shobin E, Pickel VM (2012) Cannabinoid modulation of the dopaminergic circuitry: implications for limbic and striatal output. Prog Neuropsychopharmacol Biol Psychiatry 38(1):21-29
65. Fitzgerald PB, Laird AR, Maller J, Daskalakis ZJ (2008) A meta-analytic study of changes in brain activation in depression. Hum Brain Mapp 29(6):683-695
66. Folstein M, Liu T, Peter I, Buell J, Arsenault L, Scott T, Qiu WW (2007) The homocysteine hypothesis of depression. Am J Psychiatry 164:861-867
67. Forti P, Rietti E, Pisacane N, Olivelli V, Dalmonte E, Mecocci P, Ravaglia G (2010) Blood homocysteine and risk of depression in the elderly. Arch Gerontol Geriatr 51:21-25
68. Fowler CJ, Holt S, Nilsson O, Jonsson KO, Tiger G, Jacobsson SO (2005) The endocannabinoid signaling system: pharmacological and therapeutic aspects. Pharmacol Biochem Behav 81(2):248-262
69. Gass P, Riva MA (2007) CREB, neurogenesis and depression. Bioessays 29:957-961
70. Gilbody S, Lightfoot T, Sheldon T (2007) Is low folate a risk factor for depression? A meta-analysis and exploration of heterogeneity. J Epidemiol Community Health 61:631-637
71. Gobbi G, Bambico FR, Mangieri R, Bortolato M, Campolongo P, Solinas M, Cassano T, Morgese MG, Debonnel G, Duranti A, Tontini A, Tarzia G, Mor M, Trezza V, Goldberg SR, Cuomo V, Piomelli D (2005) Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc Natl Acad Sci USA 102(51):18620-18625
72. Gorzalka BB, Hill MN (2011) Putative role of endocannabinoid signaling in the etiology of depression and actions of antidepressants. Prog Neuropsychopharmacol Biol Psychiatry 35(7):1575-1585
73. Gorzalka BB, Hill MN, Hillard CJ (2008) Regulation of endocannabinoid signaling by stress: implications for stress-related affective disorders. Neurosci Biobehav Rev 32(6):1152-1160
74. Gould TD, Manji HK (2005) Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs. Neuropsychopharmacology 30:1223-1237
75. Gould TD, Dow ER, O'Donnell KC, Chen G, Manji HK (2007) Targeting signal transduction pathways in the treatment of mood disorders: recent insights into the relevance of the Wnt pathway. CNS Neurol Disord Drug Targets 6(3):193-204
76. Green R (2011) Indicators for assessing folate and vitamin B-12 status and for monitoring the efficacy of intervention strategies. Am J Clin Nutr 94:666S-672S.
77. Griebel G, Stemmelin J, Scatton B (2005) Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents. Biol Psychiatry 57(3):261-267
78. Gu P, Defina LF, Leonard D, John S, Weiner MF, Brown ES (2012) Relationship between serum homocysteine levels and depressive symptoms: the Cooper Center Longitudinal Study. J Clin Psychiatry 73:691-695
79. Haddad JJ, Saadé NE, Safieh-Garabedian B (2002) Cytokines and neuro-immune-endocrine interactions: a role for the hypothalamic-pituitary-adrenal revolving axis. J Neuroimmunol 133(1-2):1-19
80. Heninger GR, Delgado PL, Charney DS (1996) The revised monoamine theory of depression: a modulatory role for monoamines, based on new findings from monoamine depletion experiments in humans. Pharmacopsychiatry 29(1):2-11
81. Hercher C, Turecki G, Mechawar N (2009) Through the looking glass: examining neuroanatomical evidence for cellular alterations in major depression. J Psychiatr Res 43(11):947-961
82. Hill MN, Gorzalka BB (2005) Is there a role for the endocannabinoid system in the etiology and treatment of melancholic depression? Behav Pharmacol 16(5-6):333-352
83. Hill MN, Patel S, Carrier EJ, Rademacher DJ, Ormerod BK, Hillard CJ, Gorzalka BB (2005) Down-regulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress. Neuropsychopharmacology 30(3):508-515
84. Hill MN, Sun JC, Tse MT, Gorzalka BB (2006) Altered responsiveness of serotonin receptor subtypes following long-term cannabinoid treatment. Int J Neuropsychopharmacol 9(3):277-286
85. Hill MN, Kambo JS, Sun JC, Gorzalka BB, Galea LA (2006) Endocannabinoids modulate stressinduced suppression of hippocampal cell proliferation and activation of defensive behaviours. Eur J Neurosci 24(7):1845-1849
86. Hill MN, Carrier EJ, McLaughlin RJ, Morrish AC, Meier SE, Hillard CJ, Gorzalka BB (2008) Regional alterations in the endocannabinoid system in an animal model of depression: effects of concurrent antidepressant treatment. J Neurochem 106(6):2322-2336
87. Hill MN, Miller GE, Carrier EJ, Gorzalka BB, Hillard CJ (2009) Circulating endocannabinoids and N-acyl ethanolamines are differentially regulated in major depression and following exposure to social stress. Psychoneuroendocrinology 34(8):1257-1262
88. Hill MN, Hellemans KG, Verma P, Gorzalka BB, Weinberg J (2012) Neurobiology of chronic mild stress: parallels to major depression. Neurosci Biobehav Rev 36(9):2085-2117
89. Hillard CJ, Weinlander KM, Stuhr KL (2012) Contributions of endocannabinoid signaling to psychiatric disorders in humans: genetic and biochemical evidence. Neuroscience 204:207-229
90. Holsboer F, Liebl R, Hofschuster E (1982) Repeated dexamethasone suppression test during depressive illness. Normalisation of test result compared with clinical improvement. J Affect Disord 4:93-101
91. Hroudova J, Fisar Z (2010) Activities of respiratory chain complexes and citrate synthase influenced by pharmacologically different antidepressants and mood stabilizers. Neuro Endocrinol Lett 31(3):336-342
92. Hroudová J, Fišar Z (2011) Connectivity between mitochondrial functions and psychiatric disorders. Psychiatry Clin Neurosci 65(2):130-141
93. Hroudová J, Fišar Z (2012) In vitro inhibition of mitochondrial respiratory rate by antidepressants. Toxicol Lett 213(3):345-352
94. Hungund BL, Vinod KY, Kassir SA, Basavarajappa BS, Yalamanchili R, Cooper TB, Mann JJ, Arango V (2004) Up-regulation of CB1 receptors and agonist-stimulated [35S]GTP?S binding in the prefrontal cortex of depressed suicide victims. Mol Psychiatry 9(2):184-190
95. Im HI, Kenny PJ (2012) MicroRNAs in neuronal function and dysfunction. Trends Neurosci 35(5):325-334
96. Ising M, Künzel HE, Binder EB, Nickel T, Modell S, Holsboer F (2005) The combined dexamethasone/CRH test as a potential surrogate marker in depression. Prog Neuropsychopharmacol Biol Psychiatry 29:1085-1093
97. Janssen DG, Caniato RN, Verster JC, Baune BT (2010) A psychoneuroimmunological review on cytokines involved in antidepressant treatment response. Hum Psychopharmacol 25(3):201-215
98. Jiang W, Zhang Y, Xiao L, Van Cleemput J, Ji SP, Bai G, Zhang X (2005) Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic-and antidepressantlike effects. J Clin Invest 115(11):3104-3116
99. Jimerson DC, Post RM, Carman JS, Kammen DP van, Wood JH, Goodwin FK, Bunney WE Jr (1979) CSF calcium: clinical correlates in affective illness and schizophrenia. Biol Psychiatry 14(1):37-51
100. Jou S-H, Chiu N-Y, Liu C-S (2009) Mitochondrial dysfunction and psychiatric disorders. Chang Gung Med J 32(4):370-379
101. Kasper S, McEwen BS (2008) Neurobiological and clinical effects of the antidepressant tianeptine. CNS Drugs 22(1):15-26
102. Kato T (2007) Mitochondrial dysfunction as the molecular basis of bipolar disorder: therapeutic implications. CNS Drugs 21(1):1-11
103. Kato T (2008) Role of mitochondrial DNA in calcium signaling abnormality in bipolar disorder. Cell Calcium 44(1):92-102
104. Kato T, Kato N (2000) Mitochondrial dysfunction in bipolar disorder. Bipolar Disord 2(3 Pt 1): 180-190
105. Katyare SS, Rajan RR (1995) Effect of long-term in vivo treatment with imipramine on the oxidative energy metabolism in rat brain mitochondria. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 112(3):353-357
106. Krishnan V, Nestler EJ (2008) The molecular neurobiology of depression. Nature 455(7215): 894-902
107. Krishnan V, Nestler EJ (2010) Linking molecules to mood: new insight into the biology of depression. Am J Psychiatry 167(11):1305-1320
108. Lamers F, Vogelzangs N, Merikangas KR, Jonge P de, Beekman AT, Penninx BW (2013) Evidence for a differential role of HPA-axis function, inflammation and metabolic syndrome in melancholic versus atypical depression. Mol Psychiatry. 18(6):692-699
109. Lazarou C, Kapsou M (2010) The role of folic acid in prevention and treatment of depression: an overview of existing evidence and implications for practice. Complement Ther Clin Pract 16:161-166
110. Leonard BE (2005) The HPA and immune axes in stress: the involvement of the serotonergic system. Eur Psychiatry 20(Suppl 3):S302-S306
111. Leonard BE, Myint A (2009) The psychoneuroimmunology of depression. Hum Psychopharmacol 24(3):165-175
112. Leonard B, Maes M (2012) Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci Biobehav Rev 36(2):764-785
113. Maes M, Yirmyia R, Noraberg J, Brene S, Hibbeln J, Perini G, Kubera M, Bob P, Lerer B, Maj M (2009) The inflammatory & neurodegenerative (I & ND) hypothesis of depression: leads for future research and new drug developments in depression. Metab Brain Dis 24(1):27-53
114. Maes M, Kubera M, Obuchowiczwa E, Goehler L, Brzeszcz J (2011) Depression's multiple comorbidities explained by (neuro)inflammatory and oxidative & nitrosative stress pathways. Neuro Endocrinol Lett 32(1):7-24
115. Maes M, Fišar Z, Medina M, Scapagnini G, Nowak G, Berk M (2012) New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates-Nrf2 activators and GSK-3 inhibitors. Inflammopharmacology 20(3):127-150
116. Marchalant Y, Brothers HM, Norman GJ, Karelina K, DeVries AC, Wenk GL (2009) Cannabinoids attenuate the effects of aging upon neuroinflammation and neurogenesis. Neurobiol Dis 34(2):300-307
117. Martin M, Ledent C, Parmentier M, Maldonado R, Valverde O (2002) Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology (Berl) 159(4):379-387
118. Mathew SJ, Manji HK, Charney DS (2008) Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology 33(9):2080-2092
119. Mattson MP, Shea TB (2003) Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders. Trends Neurosci 26:137-146.
120. Maurer IC, Schippel P, Volz H-P (2009) Lithium-induced enhancement of mitochondrial oxidative phosphorylation in human brain tissue. Bipolar Disord 11(5):515-522
121. Mayberg HS (1997) Limbic-cortical dysregulation: a proposed model of depression. J Neuropsychiatry Clin Neurosci 9(3):471-481
122. Mayberg HS (2003) Modulating dysfunctional limbic-cortical circuits in depression: towards development of brain-based algorithms for diagnosis and optimised treatment. Br Med Bull 65:193-207
123. Mayberg HS (2009) Targeted electrode-based modulation of neural circuits for depression. J Clin Investigation 119:717-725
124. Mayberg HS, Brannan SK, Tekell JL, Silva JA, Mahurin RK, McGinnis S, Jerabek PA (2000) Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response. Biol Psychiatry 48(8):830-843
125. McNamara RK, Ostrander M, Abplanalp W, Richtand NM, Benoit SC, Clegg DJ (2006) Modulation of phosphoinositide-protein kinase C signal transduction by omega-3 fatty acids: implications for the pathophysiology and treatment of recurrent neuropsychiatric illness. Prostaglandins Leukot Essent Fatty Acids 75(4-5):237-257
126. Mendelsohn D, Riedel WJ, Sambeth A (2009) Effects of acute tryptophan depletion on memory, attention and executive functions: a systematic review. Neurosci Biobehav Rev 33(6):926-952
127. Mendlewicz J (2009) Disruption of the circadian timing systems: molecular mechanisms in mood disorders. CNS Drugs 23(Suppl 2):15-26
128. Mesulam MM (1999) Neuroplasticity failure in Alzheimer's disease: bridging the gap between plaques and tangles. Neuron 24(3):521-529
129. Meyer JH (2012) Neuroimaging markers of cellular function in major depressive disorder: implications for therapeutics, personalized medicine, and prevention. Clin Pharmacol Ther 91(2):201-214
130. Meyer JH, Ginovart N, Boovariwala A, Sagrati S, Hussey D, Garcia A, Young T, Praschak-Rieder N, Wilson AA, Houle S (2006) Elevated monoamine oxidase a levels in the brain: an explanation for the monoamine imbalance of major depression. Arch Gen Psychiatry 63(11):1209-1216
131. Meyer JH, Wilson AA, Sagrati S, Miler L, Rusjan P, Bloomfield PM, Clark M, Sacher J, Voineskos AN, Houle S (2009) Brain monoamine oxidase A binding in major depressive disorder: relationship to selective serotonin reuptake inhibitor treatment, recovery, and recurrence. Arch Gen Psychiatry 66(12):1304-1312
132. Mill J, Petronis A (2007) Molecular studies of major depressive disorder: the epigenetic perspective. Mol Psychiatry 12(9):799-814
133. Miller AL (2008) The methylation, neurotransmitter, and antioxidant connections between folate and depression. Altern Med Rev 13:216-226
134. Mirnikjoo B, Brown SE, Kim HF, Marangell LB, Sweatt JD, Weeber EJ (2001) Protein kinase inhibition by ?-3 fatty acids. J Biol Chem 276(14):10888-10896
135. Morrish AC, Hill MN, Riebe CJ, Gorzalka BB (2009) Protracted cannabinoid administration elicits antidepressant behavioral responses in rats: role of gender and noradrenergic transmission. Physiol Behav 98(1-2):118-124
136. Nahon E, Israelson A, Abu-Hamad S, Varda SB (2005) Fluoxetine (Prozac) interaction with the mitochondrial voltage-dependent anion channel and protection against apoptotic cell death. FEBS Lett 579(22):5105-5110
137. Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM (2002) Neurobiology of depression. Neuron 34(1):13-25
138. Nikisch G (2009) Involvement and role of antidepressant drugs of the hypothalamic-pituitaryadrenal axis and glucocorticoid receptor function. Neuro Endocrinol Lett 30(1):11-16
139. Oropeza VC, Page ME, Van Bockstaele EJ (2005) Systemic administration of WIN 55, 212-2 increases norepinephrine release in the rat frontal cortex. Brain Res 1046(1-2):45-54
140. Pacher P, Mechoulam R (2011) Is lipid signaling through cannabinoid 2 receptors part of a protective system? Prog Lipid Res 50(2):193-211
141. Pariante CM (2009) Risk factors for development of depression and psychosis. Glucocorticoid receptors and pituitary implications for treatment with antidepressant and glucocorticoids. Ann N Y Acad Sci 1179:144-152
142. Parolaro D, Realini N, Vigano D, Guidali C, Rubino T (2010) The endocannabinoid system and psychiatric disorders. Exp Neurol 224(1):3-14
143. Patel S, Roelke CT, Rademacher DJ, Cullinan WE, Hillard CJ (2004) Endocannabinoid signaling negatively modulates stress-induced activation of the hypothalamic-pituitary-adrenal axis. Endocrinology 145(12):5431-5438
144. Patton GC, Coffey C, Carlin JB, Degenhardt L, Lynskey M, Hall W (2002) Cannabis use and mental health in young people: cohort study. BMJ 325(7374):1195-1198
145. Paul IA, Skolnick P (2003) Glutamate and depression: clinical and preclinical studies. Ann N Y Acad Sci 1003:250-272
146. Pedersen W (2008) Does cannabis use lead to depression and suicidal behaviours? A populationbased longitudinal study. Acta Psychiatr Scand 118(5):395-403
147. Phillips ML, Drevets WC, Rauch SL, Lane R (2003) Neurobiology of emotion perception II: implications for major psychiatric disorders. Biol Psychiatry 54(5):515-528
148. Pittenger C, Duman RS (2008) Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology 33(1):88-109
149. Porcelli S, Drago A, Fabbri C, Serretti A (2011) Mechanisms of antidepressant action: an integrated dopaminergic perspective. Prog Neuropsychopharmacol Biol Psychiatry 35(7):1532-1543
150. Przegali?ski E, Göthert M, Frankowska M, Filip M (2005) WIN 55, 212-2-induced reduction of cocaine hyperlocomotion: possible inhibition of 5-HT3 receptor function. Eur J Pharmacol 517(1-2):68-73
151. Quiroz JA, Gray NA, Kato T, Manji HK (2008) Mitochondrially mediated plasticity in the pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology 33(11):2551-2565
152. Refsum H, Nurk E, Smith AD, Ueland PM, Gjesdal CG, Bjelland I, Tverdal A, Tell GS, Nygård O, Vollset SE (2006) The Hordaland Homocysteine Study: a community-based study of homocysteine, its determinants, and associations with disease. J Nutr 136:1731S-1740S.
153. Rodràguez-Gaztelumendi A, Rojo ML, Pazos A, Daàz A (2009) Altered CB1 receptor-signaling in prefrontal cortex from an animal model of depression is reversed by chronic fluoxetine. J Neurochem 108(6):1423-1433
154. Rubino T, Vigano' D, Realini N, Guidali C, Braida D, Capurro V, Castiglioni C, Cherubino F, Romualdi P, Candeletti S, Sala M, Parolaro D (2008) Chronic ?9-tetrahydrocannabinol during adolescence provokes sex-dependent changes in the emotional profile in adult rats: behavioral and biochemical correlates. Neuropsychopharmacology 33(11):2760-2771
155. Rubino T, Realini N, Braida D, Alberio T, Capurro V, Viganò D, Guidali C, Sala M, Fasano M, Parolaro D (2009) The depressive phenotype induced in adult female rats by adolescent exposure to THC is associated with cognitive impairment and altered neuroplasticity in the prefrontal cortex. Neurotox Res 15(4):291-302
156. Ruhé HG, Mason NS, Schene AH (2007) Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies. Mol Psychiatry 12(4):331-359
157. Russo EB, Burnett A, Hall B, Parker KK (2005) Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res 30(8):1037-1043
158. Sagredo O, Ramos JA, Fernández-Ruiz J, Rodràguez ML, Miguel R de (2006) Chronic ?9-tetrahydrocannabinol administration affects serotonin levels in the rat frontal cortex. Naunyn Schmiedebergs Arch Pharmacol 372:313-317
159. Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S, Weisstaub N, Lee J, Duman R, Arancio O, Belzung C, Hen R (2003) Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 301:805-809
160. Sapolsky RM (2004) Is impaired neurogenesis relevant to the affective symptoms of depression? Biol Psychiatry 56(3):137-139
161. Savage DG, Lindenbaum J, Stabler SP, Allen RH (1994) Sensitivity of serum methylmalonic acid and total homocysteine determinations for diagnosing cobalamin and folate deficiencies. Am J Med 96:239-246
162. Savitz J, Drevets WC (2009) Bipolar and major depressive disorder: neuroimaging the developmental-degenerative divide. Neurosci Biobehav Rev 33(5):699-771
163. Savitz J, Lucki I, Drevets WC (2009) 5-HT1A receptor function in major depressive disorder. Prog Neurobiol 88(1):17-31
164. Savitz JB, Drevets WC (2013) Neuroreceptor imaging in depression. Neurobiol Dis 52:49-65
165. Schildkraut JJ (1965) The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 122(5):509-522
166. Schmidt HD, Shelton RC, Duman RS (2011) Functional biomarkers of depression: diagnosis, treatment, and pathophysiology. Neuropsychopharmacology 36(12):2375-2394
167. Schroeder FA, Lin CL, Crusio WE, Akbarian S (2007) Antidepressant-like effects of the histone deacetylase inhibitor, sodium butyrate, in the mouse. Biol Psychiatry 62(1):55-64
168. Schulz P, Steimer T (2009) Neurobiology of circadian systems. CNS Drugs 23(Suppl 2):3-13
169. Selvaraj S, Murthy NV, Bhagwagar Z, Bose SK, Hinz R, Grasby PM, Cowen PJ (2011) Diminished brain 5-HT transporter binding in major depression: a positron emission tomography study with [11C]DASB. Psychopharmacology (Berl) 213(2-3):555-562
170. Shaltiel G, Chen G, Manji HK (2007) Neurotrophic signaling cascades in the pathophysiology and treatment of bipolar disorder. Curr Opin Pharmacol 7:22-26
171. Shao L, Martin MV, Watson SJ, Schatzberg A, Akil H, Myers RM, Jones EG, Bunney WE, Vawter MP (2008) Mitochondrial involvement in psychiatric disorders. Ann Med 40(4):281-295
172. Shearman LP, Rosko KM, Fleischer R, Wang J, Xu S, Tong XS, Rocha BA (2003) Antidepressantlike and anorectic effects of the cannabinoid CB1 receptor inverse agonist AM251 in mice. Behav Pharmacol 14(8):573-582
173. Stavrovskaya IG, Narayanan MV, Zhang W, Krasnikov BF, Heemskerk J, Young SS, Blass JP, Brown AM, Beal MF, Friedlander RM, Kristal BS (2004) Clinically approved heterocyclics act on a mitochondrial target and reduce stroke-induced pathology. J Exp Med 200(2):211-222
174. Steiner MA, Wanisch K, Monory K, Marsicano G, Borroni E, Bächli H, Holsboer F, Lutz B, Wotjak CT (2008) Impaired cannabinoid receptor type 1 signaling interferes with stress-coping behavior in mice. Pharmacogenomics J 8(3):196-208
175. Stork C, Renshaw PF (2005) Mitochondrial dysfunction in bipolar disorder: evidence from magnetic resonance spectroscopy research. Mol Psychiatry 10(10):900-919
176. Tiemeier H, Tuijl HR van, Hofman A, Meijer J, Kiliaan AJ, Breteler MM (2002) Vitamin B12, folate, and homocysteine in depression: the Rotterdam Study. Am J Psychiatry 159:2099-2101
177. Tolmunen T, Hintikka J, Voutilainen S, Ruusunen A, Alfthan G, Nyyssönen K, Viinamäki H, Kaplan GA, Salonen JT (2004) Association between depressive symptoms and serum concentrations of homocysteine in men: a population study. Am J Clin Nutr 80:1574-1578
178. Tsankova N, Renthal W, Kumar A, Nestler EJ (2007) Epigenetic regulation in psychiatric disorders. Nat Rev Neurosci 8(5):355-367
179. Uher R (2008) The implications of gene-environment interactions in depression: will cause inform cure? Mol Psychiatry 13(12):1070-1078
180. Uriguën L, Pérez-Rial S, Ledent C, Palomo T, Manzanares J (2004) Impaired action of anxiolytic drugs in mice deficient in cannabinoid CB1 receptors. Neuropharmacology 46(7):966-973
181. Valvassori SS, Rezin GT, Ferreira CL, Moretti M, Goncąlves CL, Cardoso MR, Streck EL, Kapczinski F, Quevedo J (2010) Effects of mood stabilizers on mitochondrial respiratory chain activity in brain of rats treated with d-amphetamine. J Psychiatr Res 44(14):903-909
182. Velenovská M, Fišar Z (2007) Effect of cannabinoids on platelet serotonin uptake. Addict Biol 12:158-166
183. Vreeburg SA, Hoogendijk WJ, Pelt J van, Derijk RH, Verhagen JC, Dyck R van, Smit JH, Zitman FG, Penninx BW (2009) Major depressive disorder and hypothalamic-pituitary-adrenal axis activity: results from a large cohort study. Arch Gen Psychiatry 66:617-626
184. Warner-Schmidt JL, Duman RS (2006) Hippocampal neurogenesis: opposing effects of stress and antidepressant treatment. Hippocampus 16(3):239-249
185. World Health Organization (WHO) (2004) The global burden of disease, 2004 update, part 3: Disease incidence, prevalence and disability. http://www.who.int/healthinfo/globalburdendisease/GBDreport2004updatepart3.pdf
186. World Health Organization (2012) Depression. http://www.who.int/mentalhealth/management/depression/en/
187. Yasuda S, Liang MH, Marinova Z, Yahyavi A, Chuang DM. (2009) The mood stabilizers lithium and valproate selectively activate the promoter IV of brain-derived neurotrophic factor in neurons. Mol Psychiatry 14(1):51-59
188. Yildiz-Yesiloglu A, Ankerst DP (2006) Neurochemical alterations of the brain in bipolar disorder and their implications for pathophysiology: a systematic review of the in vivo proton magnetic resonance spectroscopy findings. Prog Neuropsychopharmacol Biol Psychiatry 30(6):969-995
189. Zarate CA Jr, Singh J, Manji HK (2006a) Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder. Biol Psychiatry 59(11):1006-1020
190. Zarate CA Jr , Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK (2006b) A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63(8):856-864
191. Zhang WH, Wang H, Wang X, Narayanan MV, Stavrovskaya IG, Kristal BS, Friedlander RM (2008) Nortriptyline protects mitochondria and reduces cerebral ischemia/hypoxia injury. Stroke 39(2):455-462
192. Zunszain PA, Anacker C, Cattaneo A, Carvalho LA, Pariante CM (2011) Glucocorticoids, cytokines and brain abnormalities in depression. Prog Neuropsychopharmacol Biol Psychiatry 35(3):722-729